Home > Browse Issues > Vol.37 No.4
Metabolic Actions of FGF21 and Its Clinical Outcomes
Gong Qi, Zhang Feifei, Han Yamei, Li Yu*
Key Laboratory of Nutrition and Metabolism, Institute for Nutritional Sciences, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China
Abstract: The hepatokine fibroblast growth factor 21 (FGF21) is known as a key metabolic regulator， and causes weight loss and increases insulin sensitivity. Preclinical and clinical studies have demonstrated that FGF21 serves as a potential therapeutical target for the treatment of obesity and type 2 diabetes. We discuss here tissuespecific actions and molecular mechanisms of FGF21 with a focus on the liver， adipose tissue and nervous system， as well as explore outcomes of the clinical trials of FGF21.
CN
EN